12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer
Louis PottersC. MorgensternEmil CalugaruPaul FearnAnup JassalJoseph PresserE.E. Mullen
Abstract
PPB offers acceptable 12-year BFR in patients who present with clinically localized prostate cancer. Implant dosimetry continues as an important predictor for BFR, while the addition of adjuvant therapies such as hormones and external radiation are insignificant. In patients who experience biochemical failure it appears that PSA doubling time is an important predictor of survival.
Metrics
Citation History
Topics
Related Documents
12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER
Louis PottersC. MorgensternEmil CalugaruPaul FearnAnup JassalJoseph PresserE.E. Mullen
Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer
Louis PottersC. MorgensternE.E. MullenPaul FearnArun JassalMichael W. Kattan
Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer
L POTTERSC MORGENSTERNELOISE MULLENPaul FearnA JASSALMichael W. Kattan
Distant Metastases Following Permanent Interstitial Brachytherapy for Patients With Clinically Localized Prostate Cancer
Al V. TairaGregory S. MerrickRobert W. GalbreathWayne M. ButlerJonathan H. LiefEdward AdamovichKent E. Wallner
Distant Metastases following Permanent Interstitial Brachytherapy for Patients with Clinically Localized Prostate Cancer
A.V. TairaG.S. MerrickR.W. GalbreathW.M. ButlerJ. LiefE. AdamovichK. Wallner